Mucogen (rebamipide) coated tablets 100 mg. №30

Description

Mucogen composition
active substance: rebamipide;
1 tablet contains rebamipide 100 mg;
Excipients: mannitol (E 421), croscarmellose sodium, pregelatinised starch, sodium lauryl sulfate, anhydrous citric acid, talc, magnesium stearate, hydroxypropylmethylcellulose, titanium dioxide (E 171), propylene glycol.

Dosage form
Coated tablets.

Pharmacological properties
Rebamipide increases the endogenous content of prostaglandins E2 and I2 (PGE2 and PGI2), which are contained in gastric juice, and also increases the level of prostaglandin E2 (PGE2) in the gastric mucosa, which helps to protect it from damaging factors. Rebamipide has a cytoprotective effect, proven in in vitro studies, improves blood circulation in the gastric mucosa and stimulates cell proliferation. Due to the acceleration of the activity of enzymes that stimulate the biosynthesis of macromolecular glycoproteins, rebamipide increases the amount of superficial gastric mucus. Rebamipide does not affect basal and stimulated gastric secretion.

Indication
As part of the complex treatment of chronic gastritis with increased acid-forming function of the stomach in the acute stage, erosive gastritis, functional dyspepsia.
Prevention of damage to the mucous membrane on the background of non-steroidal anti-inflammatory drugs.

Contraindication
Hypersensitivity to rebamipide or to any other component of the drug. Malignant diseases of the stomach.

Children
The drug should not be prescribed to children, as studies on the use of the drug in this age group have not been conducted.

Use during pregnancy or breastfeeding
Contraindicated during pregnancy or breastfeeding, as the safety of rebamipide in pregnant women has not been proven.
Because rebamipide is excreted in human milk, breast-feeding should be discontinued.

Method of application and dosage
Take Mucogen tablets orally with a small amount of liquid, 1 tablet (100 mg) 3 times a day.
The course of treatment is 2-4 weeks, if necessary, can be extended to 8 weeks.

Overdose
To date, there have been no cases of rebamipide overdose.
Possible nausea, vomiting, abdominal pain, diarrhea or constipation, headache, increased side effects.
In case of overdose, gastric lavage should be performed and symptomatic therapy prescribed. There is no specific antidote.

Side effects:

• From the blood and lymphatic system: leukopenia, thrombocytopenia, granulocytopenia.
• From the hepatobiliary system: liver dysfunction, jaundice, elevated liver enzymes (ALT, AST, LF, gammaglutamyltransferase).
• From the skin and subcutaneous tissue: skin rash, urticaria, eczema-like skin rash, itching, swelling.
• Neurological disorders: numbness, dizziness, drowsiness.
• From the digestive tract: constipation, bloating, diarrhea, nausea, vomiting, heartburn, pain and heaviness in the abdomen, belching, taste disturbances.
• Reproductive disorders: menstrual disorders in women, swelling and pain in the mammary glands, gynecomastia, induction of lactation, palpitations, fever, hot flashes, numbness of the tongue, cough, respiratory distress.
• Others: hypersensitivity reactions, increased urea levels, a feeling of a lump in the throat.

Expiration date
3 years.

Storage conditions
Store Mucogen at a temperature not exceeding 30 ° C in the original package.
Keep out of reach of children.